Magnetic resonance imaging-guided focal laser ablation of prostate cancer - MRI-guided focal laser ablation

Radboud Universitair Medisch Centrum0 个研究点目标入组 15 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•MRI visible index lesion (on T2-weighted MR imaging or diffusion weighted
•imaging); • maximum MRI visible lesion size is <= 20 mm large axis; • age 45 to
•76 years old; • life expectancy at inclusion of more 10 years; • diagnosis of
•prostate cancer confirmed by targeted biopsy; • criteria of low and
•intermediate risk of progression and eligibility for focal therapy; o clinical
•stage of maximum T2c o maximum biopsy Gleason score of 4 + 3 on targeted
•biopsies o serum prostate specific antigen < 15 ng/ml • patient accepting to be
•included in an active surveillance protocol at the end of the study, in
•accordance with the recommendations of good practice.

•History of prostate surgery; • history of radiation therapy or pelvic trauma;
•history of proved acute or chronic prostatitis; • history of tumor in the
•preceding 5 years (excluded: non-metastatic basal cell skin cancer); • severe
•urinary symptoms associated with benign hyperplasia of the prostate, and
•defined by an IPSS score > 18; • tumor with extra-capsular extension or
•invasion of the seminal vesicles; • patients with >2 lesions; • impossibility
•to obtain a valid informed consent; • patients unable to undergo MR imaging,
•including those with contra-indications; • contra-indications to MR guided
•focal laser therapy (colitis ulcerosa, rectal pathology or abdomino perineal
•resection); • metallic hip implant or any other metallic implant or device that
•distorts local magnetic field and compromises the quality of MR imaging; •
•patients with evidence for nodal or metastatic disease; • patients with an
•estimated Glomerular Filtration Ratio (eGFR) < 40 mL/min/1.73 m2.

发起方